Research programme: cytoprotection therapy - OnconovaAlternative Names: Ameliorex; Cytoprotection therapy research programme - Onconova; ON 01060; ON 01560; ON 01590; ON 01620
Latest Information Update: 23 Feb 2010
At a glance
- Originator Onconova Therapeutics
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chemoprotection
Most Recent Events
- 01 Jul 2004 Preclinical trials in Chemoprotection in USA (unspecified route)